Welcome to our dedicated page for Nuveen Floating Rate Income Fund news (Ticker: JFR), a resource for investors and traders seeking the latest updates and insights on Nuveen Floating Rate Income Fund stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuveen Floating Rate Income Fund's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuveen Floating Rate Income Fund's position in the market.
Nuveen Floating Rate Income Fund (NYSE: JFR) has announced a rights offering allowing current shareholders to purchase additional common shares at a discount. The Board approved issuing transferable rights to common shareholders as of January 21, 2025, with a 1-for-5 subscription ratio. The subscription price will be 95% of the average closing price over five trading days, with a minimum of 90% of NAV.
The offering aims to increase fund assets to capitalize on investment opportunities, particularly in senior loans priced below par. Key benefits include tax-efficient portfolio expansion, enhanced trading liquidity, and potential expense ratio reduction through a larger asset base. Rights will be tradeable on NYSE under symbols 'JFR RTWI' (when-issued) and 'JFR RT', with the offering expiring on February 19, 2025.
Record date shareholders who fully exercise their rights can participate in an over-subscription privilege for any remaining shares, subject to pro-rata allocation if oversubscribed.